Form 4: Insider Sells Shares in Caris Life Sciences

David D. Halbert, a Director and 10% Owner of Caris Life Sciences, Inc., reported a disposition of 40,712 common shares.

Summary

• David D. Halbert, who holds significant positions as Director, 10% Owner, and Officer of Caris Life Sciences, Inc., has reported a transaction involving the company's common stock.
• On May 15, 2026, Mr. Halbert disposed of 40,712 shares of common stock.
• The transaction was executed at a price of $15.25 per share.
• Following this transaction, Mr. Halbert beneficially owns 2,574,533 shares directly and an additional 121,025,002 shares indirectly.
• The shares withheld were for the payment of taxes related to the vesting and settlement of Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sale can be a negative indicator, the explanation of tax withholding for RSU vesting mitigates significant concern.

Negatives

• Insider David D. Halbert sold a notable number of shares, which could be interpreted negatively by the market, although the sale was for tax withholding purposes related to RSU vesting.

Risks

• The filing does not explicitly mention any new or evolving risks.
• However, any significant insider selling, even if for tax purposes, can sometimes be perceived as a lack of confidence by the market, potentially impacting share price.

Future Outlook

The filing is a Form 4 reporting a change in beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future financial performance.

Management Comments

• David D. Halbert, Founder, Chairman, and Chief Executive Officer, is the reporting person.
• Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. While this filing details a disposition by a key executive, it's crucial to understand the context, such as tax withholding for RSUs, to avoid misinterpreting it as a negative signal about the company's prospects.

Stakeholder Impact

• Shareholders: May observe the transaction, but the tax withholding explanation should provide clarity, potentially limiting negative sentiment.
• Employees: The RSU vesting and settlement process is a standard employee compensation mechanism.
• Management: The transaction is a personal financial matter for Mr. Halbert, related to his compensation.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Form 4, Insider Transaction, Caris Life Sciences, David D. Halbert, Common Stock, Beneficial Ownership, RSU Vesting, Tax Withholding